Atria Investments Inc Raises Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Atria Investments Inc grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 19.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,436 shares of the biotechnology company’s stock after purchasing an additional 393 shares during the period. Atria Investments Inc’s holdings in Ascendis Pharma A/S were worth $335,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in Ascendis Pharma A/S during the third quarter valued at approximately $30,000. Jones Financial Companies Lllp raised its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. raised its stake in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter worth $203,000.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $168.84 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37. The company has a market capitalization of $10.25 billion, a P/E ratio of -23.78 and a beta of 0.62. The company has a fifty day moving average of $138.88 and a 200 day moving average of $134.90.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. Analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $202.36.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.